Update on Human Research during COVID-19
We are updating the policy and guidelines recently distributed for modification to our procedures for conducting human subject research at the School of Medicine due to the COVID-19 pandemic. This addendum to the guidelines does not change any underlying policies but updates procedures for the implementation of those policies. It recognizes the existence of several categories of research protocols that require different responses to accomplish our continuing goals. Our primary concern is the safety of our research participants and the research team members who work for YSM and the health system.
YSM Human Subjects Research Guidance Regarding COVID-19 (Novel Coronavirus) Pandemic
Our top priority remains the safety of our research participants, patients, staff, and faculty. We continue to monitor events to determine what actions are required to keep everyone safe and informed. As the university remains open, the HRPP and YCCI continuity plan for COVID 19 as of today will be to continue normal operations of administrative functions and clinical research resources unless a change is deemed necessary. Both offices will be staffed through a combination of social distancing, rotating schedules, and working remotely from home.
Addendum 03/16/2020 21:00 h
As we make decisions on how to respond to the COVID-19 infections we want to begin by re-stating that our primary concern is the safety of our research participants and the research team members who work for YSM and the Health System. Our secondary goal is to preserve the scientific integrity of the research protocols.
Guidance on Conduct of Human Research during COVID-19
We write to inform you of current policy and guidelines for modifications to our procedures for conducting human subject research at the School of Medicine due to the COVID-19 pandemic. These include modifications as well as information on what needs to be reported to the IRB.
Yale Scientists Awarded $8.4M Grant to Develop Treatments for Women With Problem Drinking
Yale Department of Psychiatry scientists have been awarded a five-year, $8.4 million federal grant to establish a new research center at Yale that will develop treatments to help women with problem drinking.
Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation
Oral anticoagulation with warfarin after TAVR in patients with severe, symptomatic aortic stenosis at low risk for surgery appears to provide early protection against subclinical thrombosis and does so without increasing the risk of bleeding or vascular complications, according to the results of a small study presented this week at CRT 2020.Source: TCTMD
Yale Genomics Study: Helping Researchers Better Understand the Opioid Epidemic
A human genomics study led by two Yale Department of Psychiatry researchers identified specific genetic regions that link opioid exposure and dependence to neuropsychiatric traits like risk-taking behaviors, alcohol abuse, and depression.
Grilo Guest Co-Editor on Special Issue of American Psychologist
Carlos Grilo, PhD, Professor of Psychiatry and of Psychology and Director of the Yale Program for Obesity Weight and Eating Research, served as guest co-editor on a special issue titled "Obesity: Psychosocial and Behavioral Aspects of a Modern Epidemic" in the February/March issue of the American Psychologist, the official peer-reviewed scholarly journal of the American Psychological Association.
Yale School of Medicine Maintains its High National Ranking in Federal Research Funding
The 2019 total, $451,476,354, continues the school’s position in the top ten among U.S. medical schools that it has maintained each year since 2001. YSM ranked first in funding for psychiatry and dermatology; third for public health/preventive medicine and emergency medicine; fifth for radiology; sixth for neurology and ob-gyn; seventh for neurosurgery; and ninth for biochemistry, genetics, and internal medicine.
The power of shared data to better understand drug safety
This week in The BMJ, Joshua Wallach, Harlan Krumholz, and Joseph Ross published a study assessing the influence of individual patient level data, made available through ClinicalStudyDataRequest.com, on the conclusions drawn from safety-related meta-analyses examining relatively rare adverse events.Source: The BMJ Opinion